Table 1 Biological pathways enriched by up-regulated genes in OA-affected tissue from the GSE179716 and the GSE206848 data sets. Analysis performed using platform FunRich. * p < 0.05; ** p < 0.005; *** p < 0.001.

From: A preliminary bioinformatic screen to identify SRI SMC2 PSIP1 TLE4 and MSX1 as potential diagnostic and prognostic markers of osteoarthritis

Biological pathway enriched by up-regulated genes

Percentage of genes involved in enriched pathway

OA-affected chondrocytes

OA-affected synoviocytes

p

Adherens junctions interactions

0.29%

0.83%

*

Alpha9 beta1 integrin signaling events

27.18%

25.21%

*

Arf6 downstream pathway

26.60%

25.21%

*

Arf6 signaling events

26.60%

25.21%

*

Arf6 trafficking events

26.60%

25.21%

*

Aurora A signaling

2.03%

0.62%

*

Aurora B signaling

2.03%

0.62%

*

Axon guidance

6.69%

4.75%

*

Beta1 integrin cell surface interactions

30.38%

25.41%

***

Beta3 integrin cell surface interactions

2.33%

0.41%

**

Cell cycle. mitotic

9.16%

4.96%

**

Cell-extracellular matrix interactions

1.16%

0.21%

*

Class I PI3K signaling events

26.60%

25.21%

*

Class I PI3K signaling events mediated by Akt

26.60%

25.21%

*

C-MYC pathway

4.22%

2.69%

*

Cyclin D associated events in G1

1.16%

0.41%

*

DNA replication

7.12%

4.34%

*

EGF receptor (ErbB1) signaling pathway

26.60%

25.21%

*

EGFR1

2.76%

3.31%

*

EGFR-dependent endothelin signaling events

26.74%

25.21%

*

Endothelins

27.47%

25.62%

**

Epithelial-to-mesenchymal transition

5.96%

1.03%

**

ErbB receptor signaling network

26.89%

25.41%

*

ErbB1 downstream signaling

26.60%

25.21%

*

FOXM1 transcription factor network

2.18%

0.62%

*

Gene expression

0.87%

3.72%

*

Glucocorticoid receptor regulatory network

1.16%

2.07%

*

Glypican 1 network

26.89%

25.21%

*

Glypican pathway

28.05%

25.83%

**

GMCSF-mediated signaling events

26.60%

25.21%

*

Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis

0.29%

1.45%

*

IFN-gamma pathway

26.6%

25.21%

*

IGF1 pathway

26.74%

25.21%

*

IL1-mediated signaling events

5.38%

4.34%

*

IL3-mediated signaling events

26.6%

25.21%

*

IL5-mediated signaling events

26.60%

25.21%

*

Insulin pathway

26.60%

25.21%

*

Integrin cell surface interactions

3.63%

1.45%

***

Integrin family cell surface interactions

30.81%

25.41%

***

Internalization of ErbB1

26.60%

25.21%

*

LKB1 signaling events

27.33%

25.41%

*

Metabolism of RNA

1.74%

3.31%

*

Mitotic M-M/G1 phases

6.54%

4.34%

*

mTOR signaling pathway

26.60%

25.21%

*

Muscle contraction

2.76%

1.65%

***

Olfactory signaling pathway

0.15%

1.86%

*

PAR1-mediated thrombin signaling events

27.18%

25.21%

*

PD-1 signaling

0.00%

0.41%

*

PDGF receptor signaling network

26.74%

25.21%

*

PDGFR-beta signaling pathway

26.60%

25.21%

*

Plasma membrane estrogen receptor signaling

27.33%

25.21%

**

Proteoglycan syndecan-mediated signaling events

28.49%

25.83%

**

Response to elevated platelet cytosolic Ca2+

2.33%

0.83%

**

S1P1 pathway

26.60%

25.21%

*

Signaling events mediated by focal adhesion kinase

26.60%

25.21%

*

Signaling events mediated by hepatocyte growth factor receptor (c-Met)

26.60%

25.21%

*

Signaling events mediated by VEGFR1 and VEGFR2

26.74%

25.21%

*

Smooth muscle contraction

2.47%

0.83%

***

Syndecan-1-mediated signaling events

26.89%

25.21%

*

Syndecan-2-mediated signaling events

3.49%

1.86%

**

Thrombin/protease-activated receptor (PAR) pathway

27.18%

25.21%

*

TRAIL signaling pathway

27.18%

26.03%

*

Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling

26.60%

25.21%

*

VEGF and VEGFR signaling network

27.03%

25.21%

*